Drugs / MTS109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07526350 | Mar 2026 → Apr 2028 expected | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus +1 | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | METiS Pharmaceuticals | Results 引领体内TCE！剂泰科技携两项临床前研究成果亮相AACR2026 metispharma.com ↗
体外实验数据、OPM2荷瘤小鼠和在非人灵长类试验显示，该mRNA编码的CD19×BCMA×CD3三特异性TCE透过淋巴器官的特异性递送，具有强效深度、广谱的B细胞和浆细胞清除能力、抗肿瘤活性及优异的安全性特征，支持其进入首次人体临床评估。 |
| 2026-04-17 | Metis Techbio | Results 引领体内TCE！剂泰科技携两项临床前研究成果亮相AACR2026 metistechbio.com ↗
体外实验数据、OPM2荷瘤小鼠和在非人灵长类试验显示，该mRNA编码的CD19×BCMA×CD3三特异性TCE透过淋巴器官的特异性递送，具有强效深度、广谱的B细胞和浆细胞清除能力、抗肿瘤活性及优异的安全性特征，支持其进入首次人体临床评估。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | METiS Pharmaceuticals | 引领体内TCE！剂泰科技携两项临床前研究成果亮相AACR2026 metispharma.com ↗ |
| 2026-04-17 | Metis Techbio | 引领体内TCE！剂泰科技携两项临床前研究成果亮相AACR2026 metistechbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTS109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07526350 ↗ |
| Modality | Messenger RNA (mRNA) | “This is the first-in-human trial of MTS109 (mRNA-LNP).” NCT07526350 ↗ |
| Route | Subcutaneous | “subjects will receive MTS109 via subcutaneous injection” NCT07526350 ↗ |